Multiple Sclerosis.
作者信息
Reich Daniel S, Lucchinetti Claudia F, Calabresi Peter A
机构信息
From the Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda (D.S.R.), and the Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore (P.A.C.) - both in Maryland; and the Department of Neurology, Mayo Clinic, Rochester, MN (C.F.L.).
出版信息
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
Abstract
摘要
相似文献
1
Multiple Sclerosis.多发性硬化症
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
2
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.英国多发性硬化症中干扰素-β和醋酸格拉替雷的风险分担计划。6年分析结果。
Pract Neurol. 2016 Feb;16(1):4-6. doi: 10.1136/practneurol-2015-001209. Epub 2015 Oct 1.
3
Multiple sclerosis disease-modifying therapy and pregnancy.多发性硬化症疾病修正治疗与妊娠
Mult Scler. 2016 May;22(6):715-6. doi: 10.1177/1352458516642316.
4
Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?多发性硬化症药物治疗的药物经济学建模——我们是在沙上建房吗？
J Manag Care Pharm. 2007 Apr;13(3):287-9. doi: 10.18553/jmcp.2007.13.3.287.
5
Multiple sclerosis: monotherapy rules.多发性硬化症：单一疗法规则
Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886.
6
[Magnetic resonance angiography in multiple sclerosis].[磁共振血管造影在多发性硬化症中的应用]
Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(12):53-7.
7
Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.多发性硬化症：神经病理学、发病机制、磁共振成像研究及治疗的最新进展
Curr Opin Neurol. 2001 Jun;14(3):259-69. doi: 10.1097/00019052-200106000-00002.
8
Interferon beta and glatiramer acetate therapy.干扰素β和醋酸格拉替雷治疗。
Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4.
9
[Biological treatment of multiple sclerosis].[多发性硬化症的生物治疗]
Ugeskr Laeger. 2008 Jun 9;170(24):2156-9.
10
Pharmacologic management of multiple sclerosis.多发性硬化症的药物治疗
Urol Nurs. 2008 Jun;28(3):217-9.
引用本文的文献
1
Circadian Clock: A Regulator of Immunity in Autoimmune Diseases.生物钟：自身免疫性疾病中免疫的调节因子
Immun Inflamm Dis. 2025 Sep;13(9):e70246. doi: 10.1002/iid3.70246.
2
Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.视神经脊髓炎谱系障碍和多发性硬化症中脑和脊髓萎缩的时空亚型。
BMC Med. 2025 Sep 2;23(1):514. doi: 10.1186/s12916-025-04366-7.
3
Influence of OSCAR-IB Criteria on Test-Retest Reliability of Cirrus HD-OCT Retinal Thickness Measurements in People With Multiple Sclerosis.OSCAR-IB标准对多发性硬化症患者Cirrus HD-OCT视网膜厚度测量的重测信度的影响
Neurol Neuroimmunol Neuroinflamm. 2025 Nov;12(6):e200458. doi: 10.1212/NXI.0000000000200458. Epub 2025 Aug 29.
4
Flecainide mediated sodium channel blockade enhances blood brain barrier integrity and promotes neuroprotection in neuroinflammation.氟卡尼介导的钠通道阻滞增强血脑屏障完整性并在神经炎症中促进神经保护作用。
Sci Rep. 2025 Aug 23;15(1):31032. doi: 10.1038/s41598-025-15430-w.
5
Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS.多发性硬化症中的免疫微环境与靶向治疗：免疫生态位与中枢神经系统相互作用的新见解
Front Immunol. 2025 Aug 1;16:1604987. doi: 10.3389/fimmu.2025.1604987. eCollection 2025.
6
BrainAgeNeXt: Advancing brain age modeling for individuals with multiple sclerosis.BrainAgeNeXt：推进针对多发性硬化症患者的脑龄建模
Imaging Neurosci (Camb). 2025 Feb 25;3. doi: 10.1162/imag_a_00487. eCollection 2025.
7
Microstructure-informed brain tissue classification using clustering of quantitative MRI measures.利用定量磁共振成像测量的聚类进行微观结构信息的脑组织分类。
Imaging Neurosci (Camb). 2025 Apr 3;3. doi: 10.1162/imag_a_00526. eCollection 2025.
8
Investigation of BTK as a Potent Immunomodulatory Target: Exploring Novel Therapeutic Approaches for Multiple Sclerosis.将布鲁顿酪氨酸激酶作为强效免疫调节靶点的研究：探索多发性硬化症的新型治疗方法。
ACS Omega. 2025 Jul 22;10(30):33481-33496. doi: 10.1021/acsomega.5c03682. eCollection 2025 Aug 5.
9
Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis.通过TSPO-PET测量的胶质细胞激活的纵向积累可预测多发性硬化症患者后期的脑萎缩。
J Neuroinflammation. 2025 Aug 7;22(1):200. doi: 10.1186/s12974-025-03519-y.
10
Response to therapy in a cohort of patients with late-onset multiple sclerosis.一组迟发性多发性硬化症患者的治疗反应
Mult Scler J Exp Transl Clin. 2025 Jul 29;11(3):20552173251360357. doi: 10.1177/20552173251360357. eCollection 2025 Jul-Sep.
本文引用的文献
1
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.1990 - 2015年全球、区域和国家神经系统疾病负担：全球疾病负担研究2015的系统分析
Lancet Neurol. 2017 Nov;16(11):877-897. doi: 10.1016/S1474-4422(17)30299-5. Epub 2017 Sep 17.
2
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.多发性硬化症中的视网膜层分割：系统评价和荟萃分析。
Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12.
3
Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.多发性硬化症患者的肠道微生物组可使小鼠发生自发性自身免疫性脑脊髓炎。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.
4
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.多发性硬化症患者的肠道细菌调节人类 T 细胞，并在小鼠模型中加重症状。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11.
5
Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.模式 II 和模式 III 多发性硬化症是与模式 I 多发性硬化症不同的实体：来自脑脊液分析的证据。
J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z.
6
T-bet-dependent NKp46 innate lymphoid cells regulate the onset of T17-induced neuroinflammation.T 细胞转录因子 T-bet 依赖的自然杀伤细胞受体 NKp46 固有淋巴细胞调节 T17 诱导的神经炎症的发生。
Nat Immunol. 2017 Oct;18(10):1117-1127. doi: 10.1038/ni.3816. Epub 2017 Aug 14.
7
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.自体造血干细胞移植治疗多发性硬化。
Nat Rev Neurol. 2017 Jul;13(7):391-405. doi: 10.1038/nrneurol.2017.81. Epub 2017 Jun 16.
8
NG2 plays a role in neuroinflammation but is not expressed by immune cells.NG2在神经炎症中起作用，但免疫细胞不表达该物质。
Acta Neuropathol. 2017 Aug;134(2):325-327. doi: 10.1007/s00401-017-1735-5. Epub 2017 May 31.
9
Defining Disease Activity and Response to Therapy in MS.多发性硬化症中疾病活动及对治疗反应的定义
Curr Treat Options Neurol. 2017 May;19(5):20. doi: 10.1007/s11940-017-0454-5.
10
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.治疗继发进展型多发性硬化的药物干预策略。
Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0.
Zotero 插件